BioVision, Inc. – Trademark Portfolio

Entity Type: 03

BioVision, Inc. holds 18 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 16 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 10 trademarks are registered. Notable registered marks include DIAEASY, EXOPURE, EXOQUANT, BIOVISION, and EZSOLUTION. The owner is based in Mountain View, CA.

2455-D Old Middlefield Way

Mountain View, CA 94043

18 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

BioVision, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (16 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

42
Computer & Scientific (8 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does BioVision, Inc. have?

BioVision, Inc. has 18 U.S. trademarks filed with the USPTO. Of these, 10 registered, 8 abandoned.

What trademark classes does BioVision, Inc. file in?

BioVision, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are BioVision, Inc.'s most well-known trademarks?

BioVision, Inc.'s registered trademark portfolio includes well-known marks such as DIAEASY, EXOPURE, EXOQUANT, BIOVISION, and EZSOLUTION. These are among 10 currently registered trademarks in the portfolio.

What is BioVision, Inc.'s trademark registration success rate?

BioVision, Inc. has a 56% trademark registration rate, with 10 out of 18 resolved applications resulting in successful registration. Currently, 0 applications are pending review.